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Abstract
In our ongoing search toward identifying novel and synthetically simpler candidate vaccine
adjuvants, we hypothesized that the imidazo[1,2-a]pyrazines, readily accessible via the Groebke-
Blackburn-Bienaymé multicomponent reaction, would possess sufficient structural similarity with
TLR7/8-agonistic imidazoquinolines. With pyridoxal as the aldehyde component, furo[2,3-
c]pyridines, rather than the expected imidazo[1,2-a]pyridines were obtained, which were
characterized by NMR spectroscopy and crystallography. Several analogues were found to
activate TLR8-dependent NF-κB signaling. In a focused library of furo[2,3-c]pyridines, a distinct
SAR was observed with varying substituents at C2. In human PBMCs, none of the furo[2,3-
c]pyridines showed any proinflammatory cytokine induction, but upregulated several chemokine
ligand genes. In immunization studies in rabbits, the most active compound showed prominent
adjuvantic effects. The complete lack of proinflammatory cytokine induction coupled with strong
adjuvantic activity of the novel furo[2,3-c]pyridines render this hitherto unknown chemotype an
attractive class of compounds which are expected to be devoid of local or systemic reactogenicity.
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Introduction
The innate and adaptive limbs of the immune system are activated in a highly regulated and
coordinated manner to initiate host responses to invading pathogens. The innate immune
system utilizes germline-encoded pattern recognition receptors (PRRs) to discern pathogen-
associated molecular patterns (PAMPs) that are distinct to the pathogen.1–3 PRRs
encompass diverse families of receptors4 that are secreted into the extracellular environment
(such as the collectins,5 ficolins,6 pentraxins,7 alarmins8), exist in the cytosol (examples of
which include the retinoic acid–inducible gene I–like receptors,9 and the nucleotide-binding
domain and leucine-rich repeat–containing receptors10), or are present on membranes.
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Important among the transmembrane PRRs include the Toll-like receptors11 (TLRs) which
are either expressed on the plasma membrane or in the endolysosomal compartments.1 At
least 10 functional TLRs are encoded in the human genome, each with an extracellular
domain having leucine-rich repeats and a cytosolic domain called the Toll/IL-1 receptor
domain.12 The ligands for these receptors are highly conserved microbial molecules such as
lipopolysaccharides (LPS) (recognized by TLR4), lipopeptides (TLR2 in combination with
TLR1 or TLR6), flagellin (TLR5), single stranded RNA (TLR7 and TLR8), double stranded
RNA (TLR3), CpG motif-containing DNA (recognized by TLR9), and profilin present on
uropathogenic bacteria (TLR11).13 TLR1, -2, -4, -5, and -6 recognize extracellular stimuli,
while TLR3, -7, -8 and -9 function within the endolysosomal compartment.12 The activation
of TLRs by their cognate ligands leads to production of inflammatory cytokines, and up-
regulation of MHC molecules and co-stimulatory signals in antigen-presenting cells as well
as activating natural killer cells (innate immune response), which leads to the priming and
amplification of T-, and B-cell effector functions (adaptive immune responses).14–17
The discovery of TLRs has not only served to greatly accelerate our understanding of the
interplay between the innate and adaptive immune systems, but is also catalyzing novel
approaches to vaccine design and development. Several synthetic compounds have been
identified as ligands and agonists of the TLRs, leading to detailed SAR studies on these
chemotypes. For instance, the S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-R-cysteinyl-S-serine
(PAM2CS) lipopeptides18 and simpler analogues19,20 activate TLR2. Polyriboinosinic
polyribocytidylic acid (poly(I:C)) activates TLR3.21,22 Synthetic lipid A23 and various
monosaccharide lipid A analogues24,25 have been reported to activate immune cells by
utilizing TLR4. Imidazoquinolines such as imiquimod and resiquimod,26–28 2-amino-
pyrimidines such as bromopirone,29,30 guanosine analogues such as loxoribine,31 and 8-
hydroxyadenine derivatives32,33 are known to activate TLR7 and/or TLR8, while 2-
alkylthiazolo[4,5-c]quinolin- 4-amine derivatives predominantly activate TLR8 (Figure
1).34,35
Small molecule TLR7/8 activators constitute a small set of compounds occupying a very
small chemical space, and are represented by substituted imidazo/thiazolo/oxazolo/
selenazolo- [4,5-c]quinolines 1a-d, imidazo[4,5-c]pyridines 2, and a few purine and
pyrimidine derivatives (Figures 1 and 2). The identification of simpler molecules as TLR7/8
agonists may pave the way for inexpensive vaccine constructs, and we are therefore keenly
interested in exploring alternative chemotypes that are synthetically less complex. Unlike
TLR2, TLR3, TLR4,36 and TLR537 for which crystal structures are available as complexes
with their cognate ligands, a detailed structural characterization of the mode of binding of
TLR7 ligands is not yet available to guide scaffold-hopping38,39 approaches. We speculated
that 3,8-diamino-imidazo[1,2-a]pyrazines 4 (Figure 2) may bear sufficient structural
similarities to the known TLR7/8 ligands (Figures 1 and 2). These molecules are, in
principle, readily accessible in two steps (one-pot synthetic process) via the Groebke-
Blackburn-Bienaymé multicomponent reaction,32,33 and we envisaged a rapid elaboration
and screening of a library of compounds for TLR7/8 agonistic activities.
We began with the syntheses of small test-libraries of 3,8-diamino-imidazo[1,2- a]pyrazines
as well as 3-amino-imidazo[1,2-a]pyridine/pyrazines (Schemes 1 and 2). Most of these
compounds (5a–5d, 6–23) were inactive in NF-κB reporter gene assays specific for human
TLR-3, -7, -8, and -9; however compounds 26–29 obtained with pyridoxal as the aldehyde
component were found to specifically activate NF-κB signaling in TLR8-transfected
HEK293 cells. Detailed spectroscopic analyses confirmed the formation of a hitherto
unknown 2,3- diamino-furo[2,3-c]pyridine skeleton via a non-canonical pathway, which was
unambiguously confirmed by single crystal X-ray analysis. The TLR8-specific agonistic
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properties of this novel and unexpected chemotype warranted a systematic SAR, which is
presented herein.
Results and Discussion
We have previously described extensive SAR on the 1,2-disubstituted-(1H-imidazo[4,5-
c]quinoline-4-amines) class of compounds27,28,40,41 (1a, Figure 2) as TLR7/8 agonists, and
their application in designing self-adjuvanting vaccine constructs.42 In our ongoing search
toward identifying novel and synthetically simpler candidate vaccine adjuvants, we
hypothesized that the imidazo[1,2-a]pyrazines 4 (Figure 2) would possess sufficient
structural similarity with the known small molecule TLR7/8 ligands such as 1–3 (Figure 2).
These molecules are readily accessible in a one-pot, two-step process using the Groebke-
Blackburn-Bienaymé multicomponent reaction as a key step. An acid-catalyzed (HCl in
dioxane), microwave-mediated (400W, 110 °C, 10 min) reaction using 2-amino-3-
chloropyrazine (amidine component), isocyanocyclohexane (isonitrile component) and
benzaldehyde (aldehyde component) resulted, as expected, in 8-chloro-N-cyclohexyl-2-
phenylimidazo[1,2-a]pyrazin-3- amine (Scheme 1). Subsequent microwave-mediated ipso-
chloro displacement using ammonium hydroxide was unsuccessful, but conventional heating
in a sealed tube (110 °C, 16h) furnished the desired N3-cyclohexyl-2-phenylimidazo[1,2-
a]pyrazine-3,8-diamine 5a (Scheme 1) in 30% yield over two steps. Using this one-pot
process, a small set of 8-amino-imidazo[1,2-a]pyrazines 5b-5d was synthesized by varying
the aldehyde and isonitrile components (Scheme 1).
Simultaneously, a diverse test-library comprising of twenty-four compounds was also
synthesized (Scheme 2) using two amidines (2-aminopyridine and 2-aminopyrazine), three
isonitriles (2-isocyano-2-methylpropane, isocyanocyclohexane, (isocyanomethyl)benzene),
and four aldehydes (benzaldehyde, isonicotinaldehyde, salicylaldehyde and pyridoxal). The
syntheses of 6–23 (Scheme 2) proceeded smoothly. The typical Groebke reaction, carried
out at 100 °C for 20 min in CH3CN, was found to be excessively harsh for reactions using
pyridoxal (24–29), leading to low yields and charring of reaction mixtures. Reactions for
this subset of compounds progressed rapidly in 2 min under microwave conditions at 80 °C
and 600W power in CH3CN or MeOH. We noticed that only compounds 24–29 (synthesized
using pyridoxal) were fluorescent on TLC under long-wave ultraviolet radiation.
The compounds were screened in NF-κB reporter gene assays specific for human TLR-3, -4,
-5, -7, -8, and -9. The 3,8-diamino-imidazo[1,2-a]pyrazines 5a-5d as well as 3-amino-
imidazo[1,2-a]pyridine/pyrazine library members 6–23 did not display any activity in these
assays up to concentrations of 250 μM (Supporting Information). However, compounds 26–
29 (Scheme 2), obtained with the use of pyridoxal as the aldehyde component, were found to
specifically activate NF-κB signaling in human TLR8-transfected HEK293 cells (Table 1,
Figure 3), but not human TLR-3, -4, -5, -7, and -9. The NMR spectra of compounds 26–29
as well as their fluorescence properties alerted us to the possibility of the formation of a new
chemical entity with a heterocyclic system other than the classical imidazo[1,2-a]pyridine/
pyrazines during the Groebke-Blackburn-Bienaymé multicomponent reaction. In 1H NMR
spectra, the aliphatic CH of the cyclohexyl group in compounds 8/9, 14/15, and 20/21
(Scheme 2) appeared in the range of 3.0 to 3.1 δ ppm, whereas a pronounced downfield shift
of this CH proton (up to 3.85 δ ppm) was observed in compounds 26 and 27. Similar
observations were noted in another set in which the aliphatic benzylic CH2 in compounds
10/11, 16/17, and 22/23 appeared in the range of 4.2 to 4.3 δ ppm, whereas a pronounced
downfield shift of this CH2 (up to 4.76 δ ppm) was observed in compounds 28 and 29. 13C
NMR spectra of compounds 24–29 showed an unusual upfield shift of one of the aromatic
quaternary carbons in the region (90–96 δ ppm). These observations suggested a different
heterocyclic system in 24–29. Initial efforts to crystallize these molecules were
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unsuccessful. Pending continuing crystallization efforts, we sought to elucidate the
structures of these compounds via alternate routes.
Three possible cyclization products appeared plausible in this acid-catalyzed
multicomponent reaction (Panel A in Scheme 3). As mentioned earlier, NMR spectroscopic
observations for compounds 24–29 were not congruent with the 4-(3-
(cyclohexylamino)imidazo[1,2-a]pyridin-2-yl)-5-(hydroxymethyl)-2-methylpyridin-3-ol 32,
the expected product via the canonical Groebke mechanism (‘Path A’, Panel A in Scheme
3). In order to test whether the phenolic or benzylic hydroxyl groups of pyridoxal may be
involved in an alternate pathway of cyclization, we carried out a reaction using a pyridoxal
derivative 34 with its phenolic hydroxyl protected with a benzyl group (Scheme 4). This
resulted in a product with a spectral signature entirely consistent with the classical Groebke
product (5-(benzyloxy)-4- (3-(cyclohexylamino)imidazo[1,2-a]pyridin-2-yl)-6-
methylpyridin-3-yl)methanol 35, indirectly also ruling out the possibility of cyclization
involving the benzylic hydroxyl group (‘Path B’, Panel A in Scheme 3). We reasoned that
annulation via ‘Path C’ ought to lead to a furo[2,3- c]pyridine skeleton 26, and that if this
were indeed the case, this cyclization could proceed even if the amidine were to be replaced
with an aniline. We were gratified that a multicomponent reaction involving aniline, benzyl
isonitrile and pyridoxal (Scheme 5) yielded the fluorescent compound 36, whose 1H and 13C
NMR spectra resembled those of compounds 24–29. Interestingly, 36 was also found to be
weakly active (EC50 = 1.68 μM) in primary TLR8 screens (Table 1, Figure 3). Our
investigations thus far suggested the formation of a hitherto unknown furo[2,3- c]pyridine
structure, exclusively when pyridoxal was used as the aldehyde component in the Groebke-
Blackburn-Bienaymé multicomponent reaction.
Although a definitive elucidation of the reaction mechanism leading to the unexpected
furo[2,3- c]pyridine was not an immediate goal, understanding plausible mechanisms was of
interest, and was probed in some detail. Formation of the pyrano[3,4-c]pyridine 33 via
nucleophilic attack of the benzylic hydroxyl group, and its subsequent rearrangement to the
furo[2,3-c]pyridine 26 (Path D, Panel A in Scheme 3) appeared improbable.
Salicylaldehyde, which lacks the bulky hydroxymethylene group, yielded the classical
imidazo[1,2-a]pyridine 20 (confirmed by single crystal X-ray analysis, see below), rather
than the benzofuran derivative B.3 (Panel B in Scheme 3). We reasoned, therefore, that the
benzylic hydroxyl in the transition state 31 could assist cyclization via Path C (Panel A in
Scheme 3) due to steric reasons, apposing the phenolic hydroxyl with the electrophilic
carbon. In addition to the direct formation of the furo[2,3- c]pyridine 26 via path C, a
plausible alternate mechanism for this unusual cyclization route, involving the pyridine ring
system is proposed in Scheme 3 (Panel C).
After many unsuccessful attempts, a hydrochloride salt of compound 28 was crystallized as
multiply-twinned bundles in acetonitrile. A multi-domain specimen of 28 was cut from one
bundle which gave a set of diffracted intensities, permitting a crystal structure solution
(noncentrosymmetric, triclinic P1-C1 space group with eight crystallographically-
independent molecules in the asymmetric unit), but not a satisfactory refinement (Figure 4).
The structure of 28 unambiguously confirmed the furo[2,3-c]pyridine chemotype. The
structure of compound 20 (obtained with salicylaldehyde, which also possesses a phenolic
OH; Scheme 2) was also elucidated, which established the formation of a classic Groebke
product 2-(3- (cyclohexylamino)imidazo[1,2-a]pyridin-2-yl)phenol (Figure 4). These
observations clearly emphasize the significance of the additional substituents of pyridoxal,
directing the unique cyclization route leading to the furo[2,3-c]pyridine scaffold.
Thus, our initial attempts toward the synthesis of twenty-four membered imidazo[1,2-
a]pyrazine/pyridine test-library unexpectedly resulted in the formation of densely substituted
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furo[2,3-c]pyridines 24–29. Pyridoxal was found to be an indispensable component for this
cyclization reaction. Four of the six compounds obtained (26–29, Scheme 2) were found to
be active in our primary screens using TLR8-transfected HEK293 cells, while compounds
24 and 25, synthesized using 2-isocyano-2-methylpropane as one of the components, were
found to be inactive, warranting detailed structure based activity relationship investigations
for this new chemotype.
Among the active compounds 26–29, we observed that compounds 26 and 28 (derived from
2-aminopyridine), were more active than 27 and 29 (from 2-aminopyrazine; Table 1, Figure
3). We therefore selected 2-aminopyridine and pyridoxal as the invariant components and
varied the isonitrile component. We explored thirteen different isonitriles (Scheme 6),
including linear aliphatic (as in 37a and 37b), branched aliphatic (37c-37e), linear aliphatic
with silyl (37f), heteroaromatic ring (37g), ester (37h, 37i), and phosphate ester (37j)
termini, as well as aromatic substituents (37k-37m). Maximal activity was observed in 37b,
with a pentylene substituent on the C2 amine (Scheme 6, Figure 3). Diminishing the chain
length by one methylene unit (37a) decreased activity, and potency was further attenuated in
compounds with alpha-branched substituents (37d). Compound 37n, with a free NH2 at C2,
obtained by N-dealkylation of the tert-octylamine group43 of 37e with trifluoroacetic acid,
as well as compounds with aromatic substituents (37k-37m) were devoid of TLR8-
stimulatory activity (Table 1). Thus, a distinct dependence of the nature of the C2 amino
substituent on the activity profiles was observed in the furo[2,3-c]pyridines, with the C2-N-
pentyl (37b) and C2-N-(trimethylsilyl)methyl analogues (37f) displaying dominant TLR8
agonism.
As mentioned earlier, our earlier efforts at unambiguously confirming the structure of 28 did
not allow for satisfactory crystal structure refinement because of the intrinsic properties of
the crystal space group. Having synthesized thirteen additional furo[2,3-c]pyridines
(37a-37m) for purposes of delineating SAR, a parallel crystallization of these compounds
was attempted using various solvents. Suitable crystals of compound 37e were obtained as
pale yellow crystals by slow evaporation of a super-saturated solution of 37e in CH3CN/
CH3OH mixtures at room temperature. A single-domain specimen was selected and the X-
ray diffraction data was collected. The ORTEP diagram of 37e is shown in Figure 5,
confirming the non-Groebke furo[2,3-c]pyridine.
Previous mention was made that 36 (Scheme 5) was found to be weakly active (EC50 = 1.68
μM, Table 1, Figure 3B) relative to the lead compound 28, suggesting that the 2-
aminopyridine core could be substituted by anilines in this multicomponent reaction. Having
optimized the C2 group as pentylamine (derived from 1-isocyanopentane, Scheme 6), three
more furo[2,3-c]pyridines were synthesized using aniline 38a, 3-fluoroaniline 38b and 3-
nitroaniline 38c in combination with 1-isocyanopentane and pyridoxal (Scheme 7). The C2
N-pentyl analogue 38a was found to be more active than the C2 N-benzyl analogue 36
(Figure 3A and 3B, Table 1). The nitro derivative 38c was found to be as potent as the
parent compound 38a, whereas substantial gain in TLR8 activity was noticed for the fluoro-
substituted compound 38b in TLR8-specific functional assays. However, these compounds
exhibited a poorer dose-response profile (lower area-under the-curve, Figure 3). It is
pertinent to note that no stable product could be obtained by the replacement of 2-
aminopyridine with aliphatic amines.
Several TLRs are thought to signal via ligand-induced dimerization,44 as evident in the
crystal structures of TLR236,45 and TLR3.21 It is not yet understood, however, how TLR7
and TLR8, whose endogenous ligands are single-stranded viral RNA (ssRNA), recognize
and transduce signals upon engagement by small, non-polymeric molecules such as the
imidazoquinolines26,46 and the oxoadenines.47,48 In order to probe possible mechanisms of
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ligand recognition by TLR8, the dimeric compound 39 was synthesized using 1,6-
diisocyanohexane (Scheme 8); the activity of this analogue was comparable in its TLR8-
agonistic potency to the most active compounds, 28, 37a, 37b and 37f (Table 1).
We examined the cytokine-inducing properties49,50 of a subset of compounds that were
maximally active (28, 37a, 37b and 37f), all of which showed robust dose-response profiles
in primary TLR8-agonistic screens (Figure 3). We used 2-propylthiazolo[4,5-c]quinolin-4-
amine 40 (CL075) as a reference TLR8 agonist,34,35 which exhibited an EC50 of 1.32 μM
(Figure 3). In human PBMCs, only the reference thiazoloquinoline 40, but none of the
furo[2,3-c]pyridines showed any proinflammatory cytokine induction (Figure 6). We do not
yet know if the dissociation between TLR8-specific NF-κB induction on the one hand, and
lack of cytokine induction on the other is ascribable to a non-myeloid differentiation primary
response gene 88 (MyD88)-independent mechanism.51,52 However, mindful of recent
observations that proinflammatory activity is not an absolute prerequisite for adjuvantic
properties,53 and because we had previously observed potent NF-κB transactivation in a bis-
quinoline, 7-chloro-N-(4-(7- chloroquinolin-4-ylamino)butyl) quinolin-4-amine 41
(RE-660)54 unaccompanied by any proinflammatory cytokine induction, we decided to
examine two representative compounds (37b and 37f) in transcriptomal profiling
experiments. Consistent with the cytokine assays, there were no transcriptional signatures of
inflammation; however, both compounds upregulated several chemokine ligand (both
CXCL and CCL) genes (Supporting Information). Although entirely bereft of any
proinflammatory activity, the bis-quinoline compound 41 was found to be a potent adjuvant
which appears to be related to its functional agonism at CCR1.54 Given some similarities in
activity profiles between the furo[2,3-c]pyridines and 41, we decided to evaluate and
compare the adjuvantic activity of 37b alongside the reference compounds, 40 and 41.
Rabbits were immunized using bovine α-lactalbumin as a model subunit antigen.42 Anti-α-
lactalbumin IgG titers in immune sera clearly show an adjuvantic effect of 37b, with a rise-
in-titer values of >1000, comparable to the adjuvantic activities of the reference compounds,
40 and 41 (Figure 7). The complete lack of proinflammatory cytokine induction coupled
with strong adjuvantic activity of the novel furo[2,3-c]pyridines render this hitherto
unknown chemotype an exceedingly attractive class of compounds which are expected to be
devoid of local or systemic reactogenicity. Further structure-activity studies on the
furopyridines and related chemotypes are currently in progress.
Experimental Section
Chemistry
All of the solvents and reagents used were obtained commercially and used as such unless
noted otherwise. Moisture- or air-sensitive reactions were conducted under nitrogen
atmosphere in oven-dried (120 °C) glass apparatus. The solvents were removed under
reduced pressure using standard rotary evaporators. Flash column chromatography was
carried out using RediSep Rf ‘Gold’ high performance silica columns on CombiFlash Rf
instrument unless otherwise mentioned, while thin-layer chromatography was carried out on
silica gel (200 μm) CCM pre-coated aluminum sheets. The purity of all final compounds
was confirmed to be greater than 95% by HPLC-MS using a Zorbax Eclipse Plus 4.6 mm x
150 mm, 5 μm analytical reverse phase C18 column with either H2O-isopropanol or H2O-
CH3CN gradients, a diode-array detector operating in 190–500 nm range (2 nm bandpass),
and an Agilent ESI-TOF mass spectrometer (integration on total ion intensity counts, with a
mass accuracy of 10 ppm) operating in the positive ion acquisition mode.
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General procedure for the syntheses of compounds 5a-5f
Synthesis of compound 5a: N3-cyclohexyl-2-phenylimidazo[1,2-a]pyrazine-3,8-
diamine—To a solution of 2-amino-3-chloropyrazine (64 mg, 0.50 mmol) in anhydrous
acetonitrile (1 mL), were added benzaldehyde (60μL, 0.60 mmol), 4N HCl/dioxane (10μL)
and cyclohexylisonitrile (74 μL, 0.60 mmol). The reaction mixture was then heated under
microwave conditions (400 W, 110 °C) in a sealed vial for 20 min. The reaction mixture was
cooled to room temperature; ammonium hydroxide (NH3 content 28–30%, 0.5 mL) was
added and further heated at 110 °C in a sealed vial for overnight. After cooling the reaction
mixture to room temperature, the solvents were removed and the residue was purified using
column chromatography to obtain the compound 5a (47 mg, 30%). 1H NMR (500 MHz,
MeOD) δ 8.02 (dd, J = 8.2, 1.3 Hz, 2H), 7.64 (d, J = 4.8 Hz, 1H), 7.46 (dd, J= 10.9, 4.6 Hz,
2H), 7.39 – 7.28 (m, 1H), 7.21 (d, J = 4.8 Hz, 1H), 2.96 – 2.83 (m, 1H), 1.76 (d, J = 11.6 Hz,
2H), 1.71 – 1.62 (m, 2H), 1.57-1.51 (m, 1H), 1.31 – 1.19 (m, 2H), 1.19 – 1.03 (m, 3H).13C
NMR (126 MHz, MeOD) δ 151.14, 136.46, 135.17, 129.95, 129.55, 129.44, 128.67, 128.24,
128.11, 109.02, 57.87, 35.05, 26.86, 25.99. MS (ESI) calcd for C18H21N5, m/z 307.1797,
found 308.1923 (M+H)+.
Compounds 5b-5d were synthesized similarly as compound 5a.
5b: 2-([1,1′-biphenyl]-4-yl)-N3 -cyclohexylimidazo[1,2-a]pyrazine-3,8-diamine—
(44 mg, 23%) 1H NMR (500 MHz, MeOD) δ 8.13 (d, J = 8.2 Hz, 2H), 7.72 (d, J = 8.3 Hz,
2H), 7.71 – 7.67 (m, 2H), 7.64 (d, J = 4.8 Hz, 1H), 7.45 (t, J = 7.7 Hz, 2H), 7.38 – 7.31 (m,
1H), 7.22 (d, J = 4.8 Hz, 1H), 3.02 – 2.84 (m, 1H), 1.80 (d, J = 12.2 Hz, 2H), 1.69 (dd, J =
8.2, 5.3 Hz, 2H), 1.55 (s, 1H), 1.35 – 1.23 (m, 2H), 1.24 – 1.01 (m, 3H). 13C NMR (126
MHz, MeOD) δ 151.16, 141.92, 141.53, 136.10, 134.18, 130.07, 129.93, 129.56, 128.57,
128.45, 128.13, 128.02, 127.86, 109.03, 57.99, 35.12, 26.88, 26.03. MS (ESI) calcd for
C24H25N5, m/z 383.2110, found 384.2382 (M+H)+.
5c: N3-benzyl-2-butylimidazo[1,2-a]pyrazine-3,8-diamine—(10 mg, 7%) 1H NMR
(500 MHz, MeOD) δ 7.44 (d, J = 4.8 Hz, 1H), 7.29 – 7.17 (m, 5H), 7.12 (d, J = 4.8 Hz, 1H),
4.13 (s, 2H), 2.51 – 2.42 (m, 2H), 1.54 – 1.42 (m, 2H), 1.31 (dq, J = 14.8, 7.4 Hz, 2H), 0.91
(t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 150.52, 141.10, 138.98, 130.14, 129.57,
129.49, 128.81, 128.40, 127.74, 108.93, 53.28, 32.76, 27.26, 23.73, 14.26. MS (ESI) calcd
for C17H21N5, m/z 295.1797, found 296.1952 (M+H)+.
5d: 2-butyl-N3-(4-methoxyphenyl)imidazo[1,2-a]pyrazine-3,8-diamine—(36 mg,
23%) 1H NMR (500 MHz, MeOD) δ 7.26 (d, J = 4.7 Hz, 1H), 7.16 (d, J = 4.7 Hz, 1H), 6.80
– 6.69 (m, 2H), 6.49 – 6.38 (m, 2H), 3.70 (s, 3H), 2.67 (t, J = 7.6 Hz, 2H), 1.73 – 1.62 (m,
2H), 1.41 – 1.23 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 154.65,
150.75, 142.09, 140.98, 129.90, 128.28, 124.98, 115.97, 115.50, 109.10, 56.07, 32.40,
27.41, 23.46, 14.15. MS (ESI) calcd for C17H21N5O, m/z 311.1746, found 312.1905 (M
+H)+.
General procedure for the syntheses of compounds 6–29
Synthesis of compound 6: N-(tert-butyl)-2-phenylimidazo[1,2-a]pyridin-3-
amine—To a solution of 2-aminopyridine (24 mg, 0.25 mmol) in anhydrous acetonitrile,
were added benzaldehyde (28 μL, 0.28 mmol), 4N HCl/dioxane (5 μL) and tert-butyl
isonitrile (27 μL, 0.24 mmol). The reaction mixture was then heated under microwave
conditions (400 W, 110 °C) in a sealed vial for 20 min. After cooling the reaction mixture to
room temperature, the solvents were removed and the residue was purified using column
chromatography to obtain compound 6 (44 mg, 70%). 1H NMR (400 MHz, CDCl3) δ 8.23
(dt, J = 6.9, 1.2 Hz, 1H), 7.90 (dt, J = 8.1, 1.6 Hz, 2H), 7.55 (dt, J = 9.0, 1.0 Hz, 1H), 7.43 (t,
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J = 7.6 Hz, 2H), 7.31 (t, J = 7.4 Hz, 1H), 7.13 (ddd, J = 9.0, 6.6, 1.3 Hz, 1H), 6.77 (td, J =
6.8, 1.1 Hz, 1H), 3.12 (s, 1H), 1.04 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 142.15, 135.42,
135.40, 128.43, 128.32, 127.52, 124.17, 123.64, 117.48, 111.46, 101.91, 56.59, 30.43. MS
(ESI) calcd for C17H19N3, m/z 265.1579, found 266.1664 (M+H)+.
Compounds 7–29 were synthesized similarly as compound 6.
7: N-(tert-butyl)-2-phenylimidazo[1,2-a]pyrazin-3-amine—(47 mg, 74%) 1H NMR
(400 MHz, CDCl3) δ 9.00 (d, J = 1.4 Hz, 1H), 8.14 (dd, J = 4.6, 1.5 Hz, 1H), 7.91 (dd, J =
8.3, 1.3 Hz, 2H), 7.86 (d, J = 4.6 Hz, 1H), 7.46 (t, J = 7.5 Hz, 2H), 7.37 (t, J = 7.4 Hz, 1H),
3.19 (s, 1H), 1.05 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 143.54, 142.40, 137.43, 134.38,
129.04, 128.66, 128.38, 128.33, 125.17, 116.49, 57.11, 30.45. MS (ESI) calcd for
C16H18N4, m/z 266.1531, found 267.1588 (M+H)+.
8: N-cyclohexyl-2-phenylimidazo[1,2-a]pyridin-3-amine—(64 mg, 86%) 1H NMR
(500 MHz, CDCl3) δ 8.16 (d, J = 6.8 Hz, 1H), 8.05 (dd, J = 8.3, 1.2 Hz, 2H), 7.62 (d, J = 9.0
Hz, 1H), 7.45 (t, J = 7.8 Hz, 2H), 7.32 (t, J = 7.4 Hz, 1H), 7.17 (ddd, J = 8.9, 6.7, 1.2 Hz,
1H), 6.82 (td, J = 6.8, 0.9 Hz, 1H), 3.32 (s, 1H), 3.07 – 2.85 (m, 1H), 1.81 (d, J = 13.1 Hz,
2H), 1.68 (dd, J = 9.1, 3.6 Hz, 2H), 1.60 – 1.54 (m, 1H), 1.28 – 1.12 (m, 5H). 13C NMR
(126 MHz, CDCl3) δ 141.02, 135.43, 133.45, 128.74, 127.74, 127.20, 125.17, 125.04,
123.07, 116.94, 112.30, 57.02, 34.27, 25.81, 24.94. MS (ESI) calcd for C19H21N3, m/z
291.1735, found 292.1832 (M+H)+.
9: N-cyclohexyl-2-phenylimidazo[1,2-a]pyrazin-3-amine—(25 mg, 36%) 1H NMR
(500 MHz, CDCl3) δ 8.99 (d, J = 1.4 Hz, 1H), 8.01 (ddd, J = 4.6, 3.2, 1.8 Hz, 3H), 7.85 (d, J
= 4.6 Hz, 1H), 7.48 (t, J = 7.7 Hz, 2H), 7.38 (t, J = 7.4 Hz, 1H), 3.26 (s, 1H), 3.00 (m, 1H),
2.22 (s, 1H), 1.82 (dd, J = 6.6, 5.4 Hz, 2H), 1.70 (dd, J = 9.3, 3.3 Hz, 2H), 1.62 – 1.55 (m,
1H), 1.34 – 1.07 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 143.37, 139.08, 136.82, 133.62,
129.01, 128.90, 128.30, 127.42, 126.70, 115.73, 57.02, 34.41, 25.69, 24.91. MS (ESI) calcd
for C18H20N4, m/z 292.1688, found 293.1775 (M+H)+.
10: N-benzyl-2-phenylimidazo[1,2-a]pyridin-3-amine—(62 mg, 86%) 1H NMR (500
MHz, CDCl3) δ 7.98 (ddt, J = 3.7, 3.0, 1.6 Hz, 3H), 7.57 (dt, J = 9.0, 1.0 Hz, 1H), 7.45 (t, J
= 7.7 Hz, 2H), 7.39 – 7.26 (m, 6H), 7.13 (ddd, J = 9.0, 6.7, 1.3 Hz, 1H), 6.74 (td, J = 6.8, 1.1
Hz, 1H), 4.20 (d, J = 6.1 Hz, 2H), 3.52 (t, J = 6.0 Hz, 1H), 2.45 (s, 1H). 13C NMR (126
MHz, CDCl3) δ 141.57, 139.06, 136.04, 134.13, 128.84, 128.30, 127.82, 127.65, 127.16,
125.77, 124.32, 122.50, 117.52, 111.94, 52.57. MS (ESI) calcd for C20H17N3, m/z
299.1422, found 300.1490 (M+H)+.
11: N-benzyl-2-phenylimidazo[1,2-a]pyrazin-3-amine—(45 mg, 62%) 1H NMR (500
MHz, CDCl3) δ 8.98 (d, J = 1.3 Hz, 1H), 7.94 (dt, J = 8.1, 1.6 Hz, 2H), 7.82 (dd, J = 4.6, 1.4
Hz, 1H), 7.77 (d, J = 4.6 Hz, 1H), 7.47 (t, J = 7.6 Hz, 2H), 7.39 (t, J = 7.4 Hz, 1H), 7.34 –
7.27 (m, 5H), 4.23 (d, J = 2.4 Hz, 2H), 3.66 (s, 1H), 2.20 (s, 1H). 13C NMR (126 MHz,
CDCl3) δ 143.46, 138.76, 138.56, 136.79, 133.34, 129.06, 129.03, 128.99, 128.46, 128.24,
128.08, 127.42, 127.18, 115.38, 52.39. MS (ESI) calcd for C19H16N4, m/z 300.1375, found
301.1494 (M+H)+.
12: N-(tert-butyl)-2-(pyridin-4-yl)imidazo[1,2-a]pyridin-3-amine—(50 mg, 78%) 1H
NMR (500 MHz, CDCl3) δ 8.65 (d, J = 5.9 Hz, 2H), 8.20 (dt, J = 6.9, 1.0 Hz, 1H), 7.96 (dd,
J = 4.7, 1.4 Hz, 2H), 7.56 (d, J = 9.1 Hz, 1H), 7.18 (ddd, J = 9.0, 6.6, 1.2 Hz, 1H), 6.81 (td, J
= 6.8, 1.0 Hz, 1H), 3.07 (s, 1H), 1.10 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 149.69,
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142.82, 142.39, 136.46, 124.86, 124.77, 123.38, 122.17, 117.68, 111.82, 56.78, 30.38. MS
(ESI) calcd for C16H18N4, m/z 266.1531, found 267.1747 (M+H)+.
13: N-(tert-butyl)-2-(pyridin-4-yl)imidazo[1,2-a]pyrazin-3-amine—(49 mg,
76%) 1H NMR (500 MHz, CDCl3) δ 9.02 (d, J = 1.4 Hz, 1H), 8.69 (dd, J = 4.5, 1.6 Hz, 2H),
8.11 (dd, J = 4.7, 1.5 Hz, 1H), 7.94 (dd, J = 4.5, 1.6 Hz, 2H), 7.88 (d, J = 4.7 Hz, 1H), 3.12
(s, 1H), 1.10 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 150.22, 144.25, 141.96, 139.25,
137.72, 129.39, 126.24, 122.42, 116.42, 57.46, 30.61. MS (ESI) calcd for C15H17N5, m/z
267.1484, found 268.1705 (M+H)+.
14: N-cyclohexyl-2-(pyridin-4-yl)imidazo[1,2-a]pyridin-3-amine—(69 mg, 98%) 1H
NMR (500 MHz, CDCl3) δ 8.64 (dd, J = 4.6, 1.6 Hz, 2H), 8.07 (dt, J = 6.9, 1.2 Hz, 1H),
8.00 (dd, J = 4.6, 1.6 Hz, 2H), 7.54 (dt, J = 9.1, 1.0 Hz, 1H), 7.17 (ddd, J = 9.1, 6.6, 1.3 Hz,
1H), 6.81 (td, J = 6.8, 1.1 Hz, 1H), 3.11 (d, J = 3.9 Hz, 1H), 2.98 (td, J = 10.3, 4.1 Hz, 1H),
1.83 (d, J = 10.8 Hz, 2H), 1.71 (dd, J = 9.4, 3.3 Hz, 2H), 1.59 (dd, J = 7.3, 1.4 Hz, 1H), 1.32
– 1.09 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 150.03, 142.26, 142.11, 133.78, 126.92,
124.92, 122.87, 121.21, 117.99, 112.31, 57.26, 34.42, 25.75, 24.97. MS (ESI) calcd for
C18H20N4, m/z 292.1688, found 293.1854 (M+H)+.
15: N-cyclohexyl-2-(pyridin-4-yl)imidazo[1,2-a]pyrazin-3-amine—(56 mg,
80%) 1H NMR (500 MHz, CDCl3) δ 9.01 (d, J = 1.5 Hz, 1H), 8.70 (dd, J = 4.5, 1.6 Hz, 2H),
8.03 – 7.93 (m, 3H), 7.88 (d, J = 4.6 Hz, 1H), 3.21 (d, J = 5.9 Hz, 1H), 3.06 – 2.97 (m, 1H),
1.84 (d, J = 10.5 Hz, 2H), 1.72 (dd, J = 9.7, 2.6 Hz, 2H), 1.63 – 1.58 (m, 1H), 1.31 – 1.14
(m, 5H). 13C NMR (126 MHz, CDCl3) δ 150.42, 144.32, 141.25, 137.17, 135.99, 129.45,
128.03, 121.37, 115.69, 57.35, 34.55, 25.62, 24.93.MS (ESI) calcd for C17H19N5, m/z
293.1640, found 294.1894 (M+H)+.
16: N-benzyl-2-(pyridin-4-yl)imidazo[1,2-a]pyridin-3-amine—(54 mg, 75%) 1H
NMR (500 MHz, CDCl3) δ 8.62 (dd, J = 4.6, 1.6 Hz, 2H), 7.94 (dt, J = 6.9, 1.1 Hz, 1H),
7.90 (dd, J = 4.6, 1.6 Hz, 2H), 7.55 (dt, J = 9.1, 1.0 Hz, 1H), 7.34 – 7.27 (m, 5H), 7.17 (ddd,
J = 9.1, 6.6, 1.3 Hz, 1H), 6.76 (td, J = 6.8, 1.1 Hz, 1H), 4.22 (d, J = 6.1 Hz, 2H), 3.52 (t, J =
6.1 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 150.12, 142.11, 141.94, 138.64, 133.41,
128.98, 128.31, 128.06, 127.46, 125.05, 122.50, 121.13, 118.06, 112.42, 52.64. MS (ESI)
calcd for C19H16N4, m/z 300.1375, found 301.1599 (M+H)+.
17: N-benzyl-2-(pyridin-4-yl)imidazo[1,2-a]pyrazin-3-amine—(47 mg, 65%) 1H
NMR (500 MHz, CDCl3) δ 9.01 (d, J = 1.4 Hz, 1H), 8.67 (dd, J = 4.5, 1.6 Hz, 2H), 7.87 (dd,
J = 4.5, 1.6 Hz, 2H), 7.78 (dt, J = 4.6, 3.0 Hz, 2H), 7.30 (dd, J = 5.1, 1.9 Hz, 3H), 7.24 (dd, J
= 6.9, 2.6 Hz, 2H), 4.25 (d, J = 6.2 Hz, 2H), 3.66 (t, J = 6.2 Hz, 1H). 13C NMR (126 MHz,
CDCl3) δ 150.46, 144.33, 140.94, 138.23, 137.12, 135.70, 129.45, 129.14, 128.45, 128.32,
128.25, 121.34, 115.35, 52.59. MS (ESI) calcd for C18H15N5, m/z 301.1327, found
302.1474 (M+H)+.
18: 2-(3-(tert-butylamino)imidazo[1,2-a]pyridin-2-yl)phenol—(20 mg, 30%) 1H
NMR (500 MHz, CDCl3) δ 12.47 (bs, 1H), 8.19 (d, J = 6.9 Hz, 1H), 8.12 (dd, J = 7.8, 1.6
Hz, 1H), 7.51 (d, J = 9.0 Hz, 1H), 7.24 – 7.17 (m, 2H), 7.07 – 6.97 (m, 1H), 6.95 – 6.87 (m,
1H), 6.83 (td, J = 6.8, 0.9 Hz, 1H), 3.16 (bs, 1H), 1.16 (s, 9H). 13C NMR (126 MHz, CDCl3)
δ 157.07, 148.51, 140.76, 138.42, 134.51, 131.35, 129.43, 128.13, 124.82, 123.01, 118.69,
117.76, 116.96, 112.09, 109.94, 57.22, 30.50. MS (ESI) calcd for C17H19N3O, m/z
281.1528, found 282.1770 (M+H)+.
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19: 2-(3-(tert-butylamino)imidazo[1,2-a]pyrazin-2-yl)phenol—(40 mg, 59%) 1H
NMR (500 MHz, CDCl3) δ 11.87 (s, 1H), 8.98 (d, J = 1.4 Hz, 1H), 8.16 – 8.08 (m, 2H),
7.92 (d, J = 4.6 Hz, 1H), 7.31 – 7.24 (m, 1H), 7.05 (dd, J = 8.2, 1.0 Hz, 1H), 6.93 (td, J =
7.9, 1.2 Hz, 1H), 3.22 (bs, 1H), 1.17 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 157.08,
142.79, 140.85, 135.93, 130.39, 129.72, 128.31, 123.47, 119.03, 118.04, 117.65, 115.85,
57.73, 30.54. MS (ESI) calcd for C16H18N4O, m/z 282.1481, found 283.1690 (M+H)+.
20: 2-(3-(cyclohexylamino)imidazo[1,2-a]pyridin-2-yl)phenol—(30 mg, 41%) 1H
NMR (500 MHz, CDCl3) δ 13.16 (s, 1H), 8.17 (d, J = 6.8 Hz, 1H), 8.04 (dd, J = 7.8, 1.3 Hz,
1H), 7.50 (dt, J = 9.0, 0.9 Hz, 1H), 7.25 – 7.17 (m, 2H), 7.04 (dd, J = 8.2, 1.1 Hz, 1H), 6.95
– 6.89 (m, 1H), 6.87 (td, J = 6.8, 1.0 Hz, 1H), 3.17 – 2.99 (m, 2H), 1.83 (d, J = 12.5 Hz, 2H),
1.72 (dd, J = 9.5, 3.1 Hz, 2H), 1.64 – 1.57 (m, 1H), 1.32 (dd, J = 22.7, 11.7 Hz, 2H), 1.26 –
1.13 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 157.67, 139.51, 136.00, 129.25, 126.41,
124.88, 123.55, 122.62, 118.82, 117.84, 117.40, 116.64, 112.46, 57.08, 34.19, 25.83, 24.96.
MS (ESI) calcd for C19H21N3O, m/z 307.1685, found 308.1995 (M+H)+.
21: 2-(3-(cyclohexylamino)imidazo[1,2-a]pyrazin-2-yl)phenol—(54 mg, 73%) 1H
NMR (500 MHz, CDCl3) δ 12.52 (bs, 1H), 8.96 (d, J = 1.4 Hz, 1H), 8.05 (ddd, J = 9.5, 6.2,
1.5 Hz, 2H), 7.94 (d, J = 4.6 Hz, 1H), 7.30 – 7.26 (m, 1H), 7.07 (dd, J = 8.2, 1.1 Hz, 1H),
6.94 (td, J = 8.0, 1.2 Hz, 1H), 3.31 – 2.99 (m, 2H), 1.83 (d, J = 12.3 Hz, 2H), 1.77 – 1.70 (m,
2H), 1.62 (dd, J = 7.5, 2.3 Hz, 1H), 1.33 (dd, J = 21.3, 10.5 Hz, 2H), 1.27 – 1.15 (m,
3H). 13C NMR (126 MHz, CDCl3) δ 157.70, 142.41, 138.53, 134.72, 130.19, 129.97,
126.50, 125.10, 119.13, 118.09, 116.60, 115.35, 57.17, 34.34, 25.69, 24.92.MS (ESI) calcd
for C18H20N4O, m/z 308.1637, found 309.1856 (M+H)+.
22: 2-(3-(benzylamino)imidazo[1,2-a]pyridin-2-yl)phenol—(10 mg, 13%) 1H NMR
(500 MHz, CDCl3) δ 13.02 (s, 1H), 8.06 – 7.95 (m, 2H), 7.51 (d, J = 9.0 Hz, 1H), 7.42 –
7.29 (m, 5H), 7.25 – 7.17 (m, 2H), 7.06 (dd, J = 8.2, 1.0 Hz, 1H), 6.95 – 6.89 (m, 1H), 6.80
(td, J = 6.8, 0.9 Hz, 1H), 4.24 (bs, 2H), 3.41 (s, 1H).13C NMR (126 MHz, CDCl3) δ 157.75,
139.49, 138.91, 135.58, 129.38, 128.96, 128.43, 127.97, 125.95, 124.95, 124.41, 122.19,
119.04, 117.88, 117.21, 116.74, 112.51, 52.43. MS (ESI) calcd for C20H17N3O, m/z
315.1372, found 316.1611 (M+H)+.
23: 2-(3-(benzylamino)imidazo[1,2-a]pyrazin-2-yl)phenol—(43 mg, 57%) 1H NMR
(500 MHz, CDCl3) δ 12.40 (bs, 1H), 8.95 (d, J = 1.4 Hz, 1H), 8.02 (dd, J = 7.9, 1.6 Hz, 1H),
7.82 (d, J = 4.6 Hz, 1H), 7.78 (dd, J = 4.6, 1.4 Hz, 1H), 7.37 – 7.27 (m, 6H), 7.09 (dd, J =
8.3, 1.2 Hz, 1H), 6.94 (ddd, J = 7.9, 7.3, 1.2 Hz, 1H), 4.26 (d, J = 5.1 Hz, 2H), 3.53 (s,
1H). 13C NMR (126 MHz, CDCl3) δ 157.70, 142.41, 138.44, 138.07, 134.64, 130.35,
129.95, 129.12, 128.39, 128.24, 126.21, 125.76, 119.36, 118.13, 116.33, 114.97, 52.35. MS
(ESI) calcd for C19H16N4O, m/z 316.1324, found 317.1545 (M+H)+.
24: (2-(tert-butylamino)-7-methyl-3-(pyridin-2-ylamino)furo[2,3-c]pyridin-4-
yl)methanol—(13 mg, 17%) 1H NMR (400 MHz, MeOD) δ 7.97 (d, J = 4.1 Hz, 1H), 7.87
(s, 1H), 7.59 (ddd, J = 8.7, 7.2, 1.8 Hz, 1H), 6.75 (ddd, J = 7.0, 5.2, 0.7 Hz, 1H), 6.67 (d, J =
8.4 Hz, 1H), 4.61 (s, 2H), 2.72 (s, 3H), 1.53 (s, 9H). 13C NMR (126 MHz, MeOD) δ 165.65,
159.92, 147.97, 143.43, 140.55, 139.89, 132.15, 131.86, 125.53, 115.57, 110.65, 96.72,
59.04, 55.33, 30.04, 13.08. MS (ESI) calcd for C18H22N4O2, m/z 326.1743, found 327.1782
(M+H)+.
25: (2-(tert-butylamino)-7-methyl-3-(pyrazin-2-ylamino)furo[2,3-c]pyridin-4-
yl)methanol—(14 mg, 18%) 1H NMR (500 MHz, MeOD) δ 8.01 (d, J = 1.1 Hz, 1H), 7.88
(dd, J = 2.8, 1.4 Hz, 1H), 7.80 (s, 1H), 7.77 (d, J = 2.8 Hz, 1H), 4.56 (s, 2H), 2.65 (s, 3H),
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1.43 (s, 9H). 13C NMR (126 MHz, MeOD) δ 165.60, 156.50, 143.30, 143.00, 140.79,
134.76, 134.39, 132.05, 131.74, 125.39, 95.43, 58.99, 55.50, 29.98, 12.92. MS (ESI) calcd
for C17H21N5O2, m/z 327.1695, found 328.1836 (M+H)+.
26: (2-(cyclohexylamino)-7-methyl-3-(pyridin-2-ylamino)furo[2,3-c]pyridin-4-
yl)methanol—(19 mg, 22%) 1H NMR (500 MHz, MeOD) δ 8.07 (t, J = 7.4 Hz, 1H), 7.96
(s, 1H), 7.90 (d, J = 5.9 Hz, 1H), 7.29 (d, J = 8.4 Hz, 1H), 7.07 (t, J = 6.7 Hz, 1H), 4.64 (s,
2H), 3.91 – 3.79 (m, 1H), 2.75 (s, 3H), 2.05 (d, J = 8.8 Hz, 2H), 1.87 – 1.77 (m, 2H), 1.68
(d, J = 13.1 Hz, 1H), 1.48 – 1.33 (m, 4H), 1.21 (dd, J = 12.1, 9.2 Hz, 1H). 13C NMR (126
MHz, MeOD) δ 164.86, 155.98, 145.65, 143.70, 142.10, 137.34, 133.72, 132.85, 124.81,
115.77, 115.45, 89.79, 59.50, 54.25, 34.33, 26.28, 26.16, 12.97. MS (ESI) calcd for
C20H24N4O2, m/z 352.1899, found 353.2023 (M+H)+.
27: (2-(cyclohexylamino)-7-methyl-3-(pyrazin-2-ylamino)furo[2,3-c]pyridin-4-
yl)methanol—(24 mg, 28%) 1H NMR (500 MHz, MeOD) δ 8.10 (s, 1H), 7.97 (d, J = 1.4
Hz, 1H), 7.86 (s, 2H), 4.64 (s, 2H), 3.86 – 3.78 (m, 1H), 2.71 (s, 3H), 2.03 – 1.96 (m, 2H),
1.80 (dd, J = 5.3, 3.1 Hz, 2H), 1.66 (d, J = 13.0 Hz, 1H), 1.38 (t, J = 9.6 Hz, 4H), 1.23 – 1.15
(m, 1H). 13C NMR (126 MHz, MeOD) δ 165.01, 156.57, 143.09, 142.98, 141.82, 134.49,
132.10, 131.50, 125.12, 94.07, 58.98, 53.94, 34.42, 26.31, 26.20, 12.80. MS (ESI) calcd for
C19H23N5O2, m/z 353.1852, found 354.1902 (M+H)+.
28: (2-(benzylamino)-7-methyl-3-(pyridin-2-ylamino)furo[2,3-c]pyridin-4-
yl)methanol. (13—mg, 15%) 1H NMR (500 MHz, MeOD) δ 8.06 – 8.01 (m, 1H), 8.00 (s,
1H), 7.89 (d, J = 5.9 Hz, 1H), 7.44 – 7.39 (m, 2H), 7.34 (t, J = 7.5 Hz, 2H), 7.28 (t, J = 7.3
Hz, 1H), 7.23 (d, J = 8.6 Hz, 1H), 7.05 (t, J = 6.7 Hz, 1H), 4.76 (s, 2H), 4.65 (s, 2H), 2.77 (s,
3H). 13C NMR (126 MHz, MeOD) δ 165.45, 156.13, 145.31, 143.75, 142.15, 138.61,
138.18, 133.67, 133.22, 130.23, 130.00, 129.91, 128.97, 128.77, 125.32, 115.82, 115.01,
90.66, 59.42, 47.33, 12.98. MS (ESI) calcd for C21H20N4O2, m/z 360.1586, found 361.1830
(M+H)+.
29: (2-(benzylamino)-7-methyl-3-(pyrazin-2-ylamino)furo[2,3-c]pyridin-4-
yl)methanol. (15—mg, 16%) 1H NMR (500 MHz, MeOD) δ 7.99 (s, 1H), 7.94 (dd, J =
2.8, 1.5 Hz, 1H), 7.87 (s, 1H), 7.81 (d, J = 2.8 Hz, 1H), 7.37 – 7.32 (m, 2H), 7.29 (dd, J =
10.3, 5.0 Hz, 2H), 7.21 (t, J = 7.3 Hz, 1H), 4.64 (s, 2H), 4.61 (s, 2H), 2.61 (s, 3H). 13C NMR
(126 MHz, MeOD) δ 163.44, 156.59, 143.82, 143.17, 139.78, 139.64, 135.93, 134.61,
134.23, 134.16, 129.68, 128.54, 128.38, 125.19, 93.30, 59.41, 47.06, 14.34. MS (ESI) calcd
for C20H19N5O2, m/z 361.1539, found 362.1805 (M+H)+.
Synthesis of compound 34: (2-(benzylamino)-7-methyl-3-
(phenylamino)furo[2,3-c]pyridin- 4-yl)methanol—To a solution of aniline (45 μL,
0.5 mmol) in anhydrous methanol, were added pyridoxal hydrochloride (112 mg, 0.55
mmol), 4N HCl/dioxane (10 μL) and benzyl isonitrile (68 μL, 0.55 mmol). The reaction
mixture was then heated under microwave conditions (600 W, 80 °C) in a sealed vial for 2
min. After cooling the reaction mixture to room temperature, the solvents were removed and
the residue was purified using column chromatography to obtain compound 34 (84 mg,
47%).1H NMR (500 MHz, MeOD) δ 7.88 (s, 1H), 7.34 (d, J = 7.8 Hz, 2H), 7.29 (t, J = 7.6
Hz, 2H), 7.21 (t, J = 7.2 Hz, 1H), 7.09 (t, J = 7.9 Hz, 2H), 6.66 (td, J = 7.3, 0.9 Hz, 1H), 6.58
– 6.51 (m, 2H), 4.57 (s, 2H), 4.52 (s, 2H), 2.54 (s, 3H). 13C NMR (126 MHz, MeOD) δ
160.73, 150.14, 141.35, 141.10, 138.40, 137.10, 130.29, 129.51, 128.35, 128.23, 119.02,
114.15, 94.89, 60.27, 47.02, 16.66. MS (ESI) calcd for C22H21N3O2, m/z 359.1634, found
360.1832 (M+H)+.
Salunke et al. Page 11













Synthesis of compound 35: 3-(benzyloxy)-5-(hydroxymethyl)-2-
methylisonicotinaldehyde—To a solution of pyridoxalhydrochloride (500 mg, 2.45
mmol) in anhydrous DMF, were added potassium carbonate (408 mg, 2.95 mmol), and
benzyl bromide (0.35 mL, 2.95 mmol). The reaction mixture was stirred at room
temperature for overnight. After the completion of reaction, water (20 mL) was added and
the crude product obtained was extracted in ethyl acetate. The organic layer was washed
with water, dried over anhydrous sodium sulfate and evaporated. The residue was purified
using column chromatography to obtain compound 35 (100 mg, 15%) 1H NMR (500 MHz,
CDCl3) δ 8.05 (s, 1H), 7.45 – 7.32 (m, 5H), 6.64 (d, J = 1.7 Hz, 1H), 5.34 (d, J = 11.2 Hz,
1H), 5.22 (d, J = 12.7 Hz, 1H), 5.19 (d, J = 11.2 Hz, 1H), 4.99 (d, J = 12.7 Hz, 1H), 2.50 (s,
3H). 13C NMR (126 MHz, CDCl3) δ 150.88, 148.63, 136.84, 136.17, 135.53, 135.42,
128.80, 128.47, 127.74, 100.10, 74.13, 69.95, 19.38. MS (ESI) calcd for C15H15NO3, m/z
257.1052, found 258.1279 (M+H)+.
Synthesis of compound 36: (5-(benzyloxy)-4-(3-(cyclohexylamino)imidazo[1,2-
a]pyridin-2- yl)-6-methylpyridin-3-yl)methanol—To a solution of 2-aminopyridine
(24 mg, 0.25 mmol) in anhydrous acetonitrile, were added 3-(benzyloxy)-5-
(hydroxymethyl)-2-methylisonicotinaldehyde 34 (68 mg, 0.28 mmol), 4N HCl/dioxane (5
μL) and cyclohexylisonitrile (30 μL, 0.24 mmol). The reaction mixture was then heated
under microwave conditions (400 W, 110 °C) in a sealed vial for 20 min. After cooling the
reaction mixture to room temperature, solvents were removed and the residue was purified
using column chromatography to obtain compound 36 (19 mg, 17%) 1H NMR (500 MHz,
CDCl3) δ 8.41 (s, 1H), 8.07 (d, J = 6.9 Hz, 1H), 7.54 (d, J = 9.1 Hz, 1H), 7.26 – 7.15 (m,
4H), 7.02 – 6.97 (m, 2H), 6.90 (td, J = 6.8, 1.0 Hz, 1H), 4.59 (bs, 1H), 4.43 (s, 2H), 4.36 (bs,
1H), 3.88 (d, J = 7.9 Hz, 1H), 2.61 (bs, 1H), 2.58 (s, 3H), 1.85-1.75 (m, 1H), 1.70-1.65 (m,
1H), 1.50-1.40 (m, 2H), 1.37-1.28 (m, 1H), 1.22-1.05(s, 2H), 1.05-0.85 (m, 2H), 0.60 (bs,
1H). 13C NMR (126 MHz, CDCl3) δ 152.95, 150.53, 145.20, 141.29, 135.58, 129.62,
129.25, 128.76, 128.58, 128.57, 128.40, 126.28, 125.05, 123.16, 117.47, 112.53, 76.73,
61.64, 56.36, 34.32, 33.74, 25.60, 25.03, 24.53, 19.58. MS (ESI) calcd for C27H30N4O2, m/z
442.2369, found 443.2410 (M+H)+.
General procedure for the syntheses of compounds 37a-37m
Synthesis of compound 37a: (2-(butylamino)-7-methyl-3-(pyridin-2-
ylamino)furo[2,3- c]pyridin-4-yl)methanol—To a solution of 2-aminopyridine (24 mg,
0.25 mmol) in anhydrous acetonitrile, were added pyridoxal hydrochloride (56 mg, 0.28
mmol), 4N HCl/dioxane (5 μL) and n-butyl isonitrile (25 μL, 0.24 mmol). The reaction
mixture was then heated under microwave conditions (600 W, 80 °C) in a sealed vial for 2
min. After cooling the reaction mixture to room temperature, solvents were removed and the
residue was purified using column chromatography to obtain compound 37a (32 mg,
41%) 1H NMR (500 MHz, MeOD) δ 8.06 (t, J = 8.0 Hz, 1H), 7.96 (s, 1H), 7.90 (d, J = 5.8
Hz, 1H), 7.29 (d, J = 8.5 Hz, 1H), 7.07 (t, J = 6.6 Hz, 1H), 4.65 (s, 2H), 3.56 (t, J = 7.1 Hz,
2H), 2.75 (s, 3H), 1.75 – 1.61 (m, 2H), 1.49 – 1.35 (m, 2H), 0.96 (t, J = 7.4 Hz, 3H). 13C
NMR (126 MHz, MeOD) δ 165.68, 155.98, 145.61, 143.66, 142.08, 137.58, 133.67, 132.87,
124.84, 115.82, 115.31, 90.01, 59.50, 43.64, 32.79, 20.93, 13.99, 12.96. MS (ESI) calcd for
C18H22N4O2, m/z 326.1743, found 327.1925 (M+H)+.
Compounds 37b-37mwere synthesized similarly as compound 37a.
37b: (7-methyl-2-(pentylamino)-3-(pyridin-2-ylamino)furo[2,3-c]pyridin-4-
yl)methanol—(27 mg, 33%) 1H NMR (500 MHz, MeOD) δ 8.06 (t, J = 8.0 Hz, 1H), 7.96
(s, 1H), 7.91 (d, J = 5.9 Hz, 1H), 7.28 (d, J = 8.5 Hz, 1H), 7.07 (t, J = 6.6 Hz, 1H), 4.65 (s,
2H), 3.56 (t, J = 7.1 Hz, 2H), 2.75 (s, 3H), 1.75 – 1.64 (m, 2H), 1.38 (d, J = 3.6 Hz, 4H),
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0.92 (t, J = 6.9 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 165.68, 156.04, 145.55, 143.66,
142.09, 137.74, 133.66, 132.85, 124.85, 115.82, 115.25, 90.09, 59.49, 43.90, 30.42, 29.98,
23.31, 14.32, 12.95.MS (ESI) calcd for C19H24N4O2, m/z 340.1899, found 341.2058 (M
+H)+.
37c: (2-(isopropylamino)-7-methyl-3-(pyridin-2-ylamino)furo[2,3-c]pyridin-4-
yl)methanol—(20 mg, 27%) 1H NMR (500 MHz, MeOD) δ 8.05 (t, J = 8.0 Hz, 1H), 7.95
(s, 1H), 7.90 (d, J = 5.9 Hz, 1H), 7.26 (d, J = 8.6 Hz, 1H), 7.05 (t, J = 6.7 Hz, 1H), 4.63 (s,
2H), 4.25 (dt, J = 13.0, 6.5 Hz, 1H), 2.74 (s, 3H), 1.33 (d, J = 6.5 Hz, 6H). 13C NMR (126
MHz, MeOD) δ 164.96, 156.16, 145.41, 143.72, 142.06, 137.79, 133.63, 132.82, 124.86,
115.77, 115.24, 90.04, 59.48, 47.16, 23.12, 12.94. MS (ESI) calcd for C17H20N4O2, m/z
312.1586, found 313.1740 (M+H)+.
37d: (7-methyl-2-(pentan-2-ylamino)-3-(pyridin-2-ylamino)furo[2,3-c]pyridin-4-
yl)methanol—(34 mg, 42%) 1H NMR (500 MHz, MeOD) δ 7.99 (t, J = 8.0 Hz, 1H), 7.88
(s, 1H), 7.83 (d, J = 5.2 Hz, 1H), 7.20 (d, J = 7.3 Hz, 1H), 7.00 (t, J = 6.7 Hz, 1H), 4.56 (s,
2H), 4.03 (dq, J = 12.9, 6.5 Hz, 1H), 2.66 (s, 3H), 1.60 – 1.41 (m, 2H), 1.38 – 1.26 (m, 2H),
1.23 (d, J = 6.6 Hz, 3H), 0.86 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 165.14,
155.98, 145.72, 143.66, 142.17, 137.38, 133.77, 132.84, 124.79, 115.82, 115.41, 89.73,
59.52, 51.18, 39.97, 21.53, 20.53, 14.15, 12.94. MS (ESI) calcd for C19H24N4O2, m/z
340.1899, found 341.2077 (M+H)+.
37e: (7-methyl-3-(pyridin-2-ylamino)-2-((2,4,4-trimethylpentan-2-
yl)amino)furo[2,3- c]pyridin-4-yl)methanol—(33 mg, 36%) 1H NMR (500 MHz,
MeOD) δ 8.08 (t, J = 8.0 Hz, 1H), 7.99 (s, 1H), 7.90 (s, 1H), 7.27 (s, 1H), 7.08 (dd, J = 7.0,
6.4 Hz, 1H), 4.63 (s, 2H), 2.78 (s, 3H), 1.95 (d, J = 12.9 Hz, 2H), 1.60 (s, 6H), 1.00 (s,
9H). 13C NMR (126 MHz, MeOD) δ 165.37, 156.14, 145.64, 143.96, 141.40, 137.05,
133.87, 132.93, 124.92, 115.77, 115.62, 90.82, 59.88, 59.51, 53.31, 32.62, 31.82, 30.73,
13.06.MS (ESI) calcd for C22H30N4O2, m/z 382.2369, found 383.2541 (M+H)+.
37f: (7-methyl-3-(pyridin-2-ylamino)-2-(((trimethylsilyl)methyl)amino)furo[2,3-
c]pyridin-4- yl)methanol—(24 mg, 28%) 1H NMR (500 MHz, MeOD) δ 8.03 (t, J = 8.0
Hz, 1H), 7.91-7.90 (m, 2H), 7.24 (d, J = 8.7 Hz, 1H), 7.04 (t, J = 6.6 Hz, 1H), 4.62 (s, 2H),
3.11 (s, 2H), 2.72 (s, 3H), 0.12 (s, 9H). 13C NMR (126 MHz, MeOD) δ 165.66, 156.25,
145.27, 143.32, 142.02, 138.19, 133.57, 132.16, 124.28, 115.77, 115.00, 90.25, 59.52,
34.64, 12.94, -2.60. MS (ESI) calcd for C18H24N4O2Si, m/z 356.1669, found 357.1815 (M
+H)+.
37g: (7-methyl-2-((2-morpholinoethyl)amino)-3-(pyridin-2-ylamino)furo[2,3-
c]pyridin-4- yl)methanol—(9 mg, 10%) 1H NMR (500 MHz, MeOD) δ 8.03 (s, 2H),
7.93 (d, J = 5.8 Hz, 1H), 7.27 (d, J = 7.3 Hz, 1H), 7.05 (t, J = 6.5 Hz, 1H), 4.66 (s, 2H),
4.06-3.95 (m, 6H), 3.54 (bs, 2H), 3.42 (bs, 4H), 2.80 (s, 3H). 13C NMR (126 MHz, MeOD)
δ 165.51, 156.26, 145.10, 143.92, 141.95, 138.27, 134.09, 133.62, 126.01, 115.97, 115.07,
90.35, 64.80, 59.39, 57.37, 53.45, 37.84, 13.21. MS (ESI) calcd for C20H25N5O3, m/z
383.1957, found 384.2132 (M+H)+.
37h: Ethyl 2-((4-(hydroxymethyl)-7-methyl-3-(pyridin-2-ylamino)furo[2,3-
c]pyridin-2- yl)amino)acetate—(21 mg, 25%) 1H NMR (500 MHz, MeOD) δ 8.07 (t, J
= 8.0 Hz, 1H), 8.03 (s, 1H), 7.91 (d, J = 6.1 Hz, 1H), 7.29 (d, J = 8.9 Hz, 1H), 7.08 (t, J = 6.7
Hz, 1H), 4.66 (s, 2H), 4.36 (s, 2H), 4.18 (q, J = 7.1 Hz, 2H), 2.74 (s, 3H), 1.25 (t, J = 7.1 Hz,
3H). 13C NMR (126 MHz, MeOD) δ 170.68, 165.42, 155.75, 145.81, 143.87, 142.15,
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137.71, 133.94, 133.89, 125.93, 115.98, 115.25, 91.02, 62.95, 59.42, 44.55, 14.48, 13.03.
MS (ESI) calcd for C18H20N4O4, m/z 356.1485, found 357.1738 (M+H)+.
37i: tert-butyl 3-((4-(hydroxymethyl)-7-methyl-3-(pyridin-2-ylamino)furo[2,3-
c]pyridin-2- yl)amino)propanoate—(20 mg, 21%) 1H NMR (500 MHz, MeOD) δ 8.08
(t, J = 8.0 Hz, 1H), 8.00 (s, 1H), 7.91 (d, J = 5.8 Hz, 1H), 7.29 (d, J = 7.8 Hz, 1H), 7.08 (t, J
= 6.7 Hz, 1H), 4.66 (s, 2H), 3.80 (t, J = 6.4 Hz, 2H), 2.78 (s, 3H), 2.67 (t, J = 6.7 Hz, 2H),
1.42 (s, 9H). 13C NMR (126 MHz, MeOD) δ 171.99, 165.49, 155.86, 145.77, 143.76,
142.08, 137.49, 133.79, 133.30, 125.17, 115.86, 115.36, 90.25, 82.28, 59.49, 39.67, 36.03,
28.31, 13.02. MS (ESI) calcd for C21H26N4O4, m/z 398.1954, found 399.2128 (M+H)+.
37j: Diethyl (((4-(hydroxymethyl)-7-methyl-3-(pyridin-2-ylamino)furo[2,3-
c]pyridin-2- yl)amino)methyl)phosphonate—(13 mg, 13%) 1H NMR (500 MHz,
MeOD) δ 8.08 – 8.00 (m, 2H), 7.95 (d, J = 5.7 Hz, 1H), 7.23 (d, J = 4.9 Hz, 1H), 7.06 (t, J =
6.5 Hz, 1H), 4.69 (s, 2H), 4.24 – 4.16 (m, 4H), 4.09 (d, J = 10.6 Hz, 2H), 2.81 (s, 3H), 1.33
(t, J = 7.0 Hz, 6H). 13C NMR (126 MHz, MeOD) δ 164.98, 156.41, 145.04, 143.68, 142.06,
139.12, 133.83, 133.71, 125.96, 115.97, 114.67, 91.93, 64.56 (d, J = 6.9 Hz), 59.37, 39.02
(d, J = 158.9 Hz), 16.78 (d, J = 5.6 Hz), 13.09. MS (ESI) calcd for C19H25N4O5P, m/z
420.1563, found 421.1672 (M+H)+.
37k: (2-((4-methoxyphenyl)amino)-7-methyl-3-(pyridin-2-ylamino)furo[2,3-
c]pyridin-4- yl)methanol—(13 mg, 14%) 1H NMR (500 MHz, MeOD) δ 7.99 – 7.87 (m,
2H), 7.62 (t, J = 7.8 Hz, 1H), 7.33 (d, J = 8.8 Hz, 2H), 6.90 (d, J = 8.8 Hz, 2H), 6.77 (t, J =
6.3 Hz, 2H), 4.66 (s, 2H), 3.77 (s, 3H), 2.71 (s, 3H). 13C NMR (126 MHz, MeOD) δ 162.79,
159.21, 158.92, 146.57, 143.34, 141.31, 140.61, 132.84, 132.22, 130.80, 126.51, 124.33,
115.64, 115.43, 111.46, 96.53, 62.30, 58.97, 55.97, 13.06. MS (ESI) calcd for C21H20N4O3,
m/z 376.1535, found 377.1694 (M+H)+.
37l: (2-((2-chloro-6-methylphenyl)amino)-7-methyl-3-(pyridin-2-
ylamino)furo[2,3- c]pyridin-4-yl)methanol—(27 mg, 28%) 1H NMR (500 MHz,
MeOD) δ 8.10 (s, 1H), 7.90 (dd, J = 20.4, 6.6 Hz, 2H), 7.28 – 7.15 (m, 3H), 7.03 (t, J = 6.6
Hz, 1H), 6.95 (s, 1H), 4.70 (s, 2H), 2.75 (s, 3H), 2.32 (s, 3H). 13C NMR (126 MHz, MeOD)
δ 162.57, 155.17, 145.80, 144.21, 142.68, 139.93, 136.98, 134.45, 133.96, 133.78, 132.14,
130.74, 128.65, 126.80, 115.93, 114.82, 91.45, 59.30, 18.71, 13.11. MS (ESI) calcd for
C21H19ClN4O2, m/z 394.1197, found 395.1349 (M+H)+.
37m: (S)-(7-methyl-2-((1-phenylethyl)amino)-3-(pyridin-2-ylamino)furo[2,3-
c]pyridin-4- yl)methanol—(28 mg, 31%) 1H NMR (500 MHz, MeOD) δ 7.92 (s, 1H),
7.89 (t, J = 8.0 Hz, 1H), 7.90 – 7.81 (m, 1H), 7.38 (d, J = 7.6 Hz, 2H), 7.29 (t, J = 7.4 Hz,
2H), 7.21 (t, J = 7.2 Hz, 1H), 7.05 (d,J = 6.1 Hz, 1H), 6.94 (t, J = 6.4 Hz, 1H), 5.20 (q, J =
6.8 Hz, 1H), 4.58 (s, 2H), 2.68 (s, 3H), 1.60 (d, J = 6.9 Hz, 3H). 13C NMR (126 MHz,
MeOD) δ 164.81, 157.13, 144.72, 143.97, 143.61, 142.11, 140.61, 133.20, 132.80, 129.92,
128.71, 126.98, 125.52, 115.70, 113.93, 91.91, 59.24, 54.49, 23.31, 12.88. MS (ESI) calcd
for C22H22N4O2, m/z 374.1743, found 375.1931 (M+H)+.
Synthesis of compound (37n): ((2-amino-7-methyl-3-(pyridin-2-
ylamino)furo[2,3-c]pyridin- 4-yl)methanol—The solution of compound 37e (95 mg,
0.25 mmol) in TFA/CH2Cl2 (50%, 4 mL) was stirred at room temperature for 6 h. The
solvents were removed and the residue obtained was column purified to afford compound
37n (56 mg, 84%).1H NMR (500 MHz, MeOD) δ 7.91 – 7.86 (m, 2H), 7.81 (t, J = 7.9 Hz,
1H), 6.96 (d, J = 8.6 Hz, 1H), 6.87 (t, J = 6.5 Hz, 1H), 4.61 (s, 2H), 2.66 (s, 3H). 13C NMR
(126 MHz, MeOD) δ 167.39, 157.68, 143.36, 143.14, 142.12, 132.82, 132.44, 125.47,
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115.59, 113.10, 92.54, 59.18, 12.80. MS (ESI) calcd for C14H14N4O2, m/z 270.1117, found
271.1310 (M+H)+.
Compounds 38a-38cwere synthesized similarly as compound 34.
38a: (7-methyl-2-(pentylamino)-3-(phenylamino)furo[2,3-c]pyridin-4-
yl)methanol—(117 mg, 70%) 1H NMR (500 MHz, MeOD) δ 7.85 (s, 1H), 7.14 (dd, J =
8.6, 7.4 Hz, 2H), 6.71 (tt, J = 7.4, 1.0 Hz, 1H), 6.60 (dd, J = 8.6, 1.0 Hz, 2H), 4.65 – 4.59 (m,
2H), 3.51 (t, J = 7.1 Hz, 2H), 2.68 (s, 3H), 1.72 – 1.57 (m, 2H), 1.41 – 1.28 (m, 4H), 0.95 –
0.84 (m, 3H). 13C NMR (126 MHz, MeOD) δ 165.54, 149.56, 143.22, 141.35, 133.46,
132.44, 130.44, 125.33, 119.45, 114.08, 96.74, 59.31, 43.42, 31.00, 29.94, 23.33, 14.34,
13.48. MS (ESI) calcd for C20H25N3O2, m/z 339.1947, found 340.2087 (M+H)+.
38b: (3-((3-fluorophenyl)amino)-7-methyl-2-(pentylamino)furo[2,3-c]pyridin-4-
yl) methanol—(70 mg, 82%) 1H NMR (500 MHz, MeOD) δ 7.81 (s, 1H), 7.06 (td, J = 8.2,
6.7 Hz, 1H), 6.42 – 6.32 (m, 2H), 6.23 (d, J = 11.5 Hz, 1H), 4.60 (s, 2H), 3.46 (t, J = 7.1 Hz,
2H), 2.65 (s, 3H), 1.59 (p, J = 7.1 Hz, 2H), 1.31 – 1.23 (m, 4H), 0.83 (t, J = 7.0 Hz, 3H). 13C
NMR (126 MHz, MeOD) 166.34, 165.62 (d, J = 242.1 Hz), 151.55 (d, J = 10.4 Hz), 142.79,
142.04, 131.84 (d, J = 10.1 Hz), 131.65, 131.28, 125.42, 110.01,105.58 (d, J = 21.8 Hz),
100.74 (d, J = 25.8 Hz), 96.47, 58.95, 43.43, 30.83, 29.93, 23.33, 14.35, 12.79. MS (ESI)
calcd for C20H24FN3O2, m/z 357.1853, found 358.2013 (M+H)+.
38c: (7-methyl-3-((3-nitrophenyl)amino)-2-(pentylamino)furo[2,3-c]pyridin-4-
yl)methanol—(34 mg, 37%) 1H NMR (500 MHz, MeOD) δ 7.90 (s, 1H), 7.49 (dd, J = 8.1,
2.2 Hz, 1H), 7.34 (s, 1H), 7.31 (t, J = 8.1 Hz, 1H), 6.95 (d, J = 8.0 Hz, 1H), 4.54 (s, 2H),
3.41 (t, J = 7.0 Hz, 2H), 2.56 (s, 3H), 1.65 – 1.52 (m, 2H), 1.30 (dd, J = 8.5, 4.8 Hz, 4H),
0.86 (t, J = 6.5 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 160.86, 151.59, 150.89, 144.93,
141.84, 138.47, 136.71, 131.12, 124.51, 120.06, 113.05, 107.81, 92.23, 60.13, 43.34, 31.50,
30.02, 23.40, 16.73, 14.35. MS (ESI) calcd for C20H24N4O4, m/z 384.1798, found 385.1950
(M+H)+.
Synthesis of compound (39): 2,2′-(hexane-1,6-diylbis(azanediyl))bis(7-
methyl-3-(pyridin-2- ylamino)furo[2,3-c]pyridine-4,2-diyl))dimethanol—To a
solution of 2-aminopyridine (48 mg, 0.50 mmol) in anhydrous acetonitrile, were added
pyridoxalhydrochloride (112 mg, 0.56 mmol), 4N HCl/dioxane (10 μL) and 1,6-
diisocyanohexane (36 μL, 0.24 mmol). The reaction mixture was then heated under
microwave conditions (600 W, 80 °C) in a sealed vial for 2 min. After cooling the reaction
mixture to room temperature, solvent was removed and the residue was purified using
column chromatography to obtain compound 39 (21 mg, 7%). 1H NMR (500 MHz, MeOD)
δ 8.07 (t, J = 8.0 Hz, 2H), 7.97 (s, 2H), 7.90 (d, J = 5.6 Hz, 2H), 7.31 (d, J = 5.6 Hz, 2H),
7.07 (t, J = 6.7 Hz, 2H), 4.64 (s, 4H), 3.57 (t, J = 7.0 Hz, 4H), 2.75 (s, 6H), 1.78 – 1.65 (m,
4H), 1.46 (s, 4H). 13C NMR (126 MHz, MeOD) δ 165.67, 155.95, 145.66, 143.71, 142.10,
137.48, 133.70, 132.91, 124.87, 115.83, 115.43, 90.05, 59.50, 43.86, 30.65, 27.48, 13.02.
MS (ESI) calcd for C34H38N8O4, m/z 622.3016, found 623.3187 (M+H)+.
X-ray crystallographic structural studies of 20, 28, and 37e—Crystals for
compound 28 utilize the non-centrosymmetric triclinic space group P1-C1 with eight
crystallographically-independent molecules in the asymmetric unit. They also invariably
form multiply-twinned bundles. After many unsuccessful attempts, a multi-domain
specimen of 28 was cut from one of these bundles that gave a set of diffracted intensities
that permitted a crystal structure solution but not a satisfactory refinement. Full sets of
unique diffracted intensities were measured for single-domain specimens of compounds 20
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and 37e using monochromated CuKα radiation (λ= 1.54178 Å) on a Bruker Proteum Single
Crystal Diffraction System equipped with Helios multilayer optics, an APEX II CCD
detector and a Bruker MicroStar microfocus rotating anode x-ray source operating at 45kV
and 60mA. Diffracted intensities were obtained with the Bruker program SAINT and the
structures were solved using “direct methods” techniques incorporated into the Bruker
SHELXTL Version 2010.3-0 software package. All stages of weighted full-matrix least-
squares refinement were performed using the SHELXTL software with Fo2 data. The final
structural model for compounds 20 and 37e incorporated anisotropic thermal parameters for
all non-hydrogen atoms and isotropic thermal parameters for all hydrogen atoms. The
respective asymmetric units consist of four molecules of 20; one molecule of 37e. All
hydrogen atoms for 37e and hydrogen atoms of 20 that are bonded to amine nitrogens (one
in each molecule) were located in a difference Fourier map and included in the structural
model as independent isotropic atoms whose parameters were allowed to vary in least-
squares refinement cycles. All hydroxyl hydrogens for 20 were placed at idealized sp3-
hybridized positions with an O-H bond length of 0.84 Å; the hydroxyl group was then
allowed to rotate about its O-C bond during least squares refinement cycles. The remaining
hydrogen atoms for 20 were included in the structural model as idealized atoms (assuming
sp2- or sp3-hybridization of the carbon or nitrogen atoms and C-H bond lengths of 0.95 to
1.00 Å or N-H bond lengths of 0.88 Å). The isotropic thermal parameters of all idealized
hydrogen atoms for 20 were fixed at values 1.2 (nonmethyl) or 1.5 (methyl) times the
equivalent isotropic thermal parameter of the carbon, nitrogen or oxygen atom to which they
are covalently bonded.
Human TLR-3/-4/-5/-7/-8/-9 Reporter Gene assays (NF-κB induction)—The
induction of NF- κB was quantified using human TLR-3/-4/-5/-7/-8/-9-specific HEK-Blue™
reporter gene assays as previously described by us.27,40,49 HEK293 cells stably co-
transfected with the appropriate hTLR and secreted alkaline phosphatase (sAP) were
maintained in HEK-Blue™ Selection medium containing zeocin and normocin. Stable
expression of secreted alkaline phosphatase (sAP) under control of NF-κB/AP-1 promoters
is inducible by appropriate TLR agonists, and extracellular sAP in the supernatant is
proportional to NF-κB induction. HEK-Blue™ cells were incubated at a density of ~105
cells/mL in a volume of 80 WL/well, in 384-well, flat-bottomed, cell culture-treated
microtiter plates until confluency was achieved, and subsequently stimulated with graded
concentrations of stimuli. sAP was assayed spectrophotometrically using an alkaline
phosphatase-specific chromogen (present in HEK-detection medium as supplied by the
vendor) at 620 nm.
Immunoassays for cytokines—Fresh human peripheral blood mononuclear cells
(hPBMC) were isolated from human blood obtained by venipuncture with informed consent
and as per institutional guidelines on Ficoll-Hypaque gradients as described elsewhere.55
Aliquots of PBMCs (105 cells in 100 μL/well) were stimulated for 12 h with graded
concentrations of test compounds. Supernatants were isolated by centrifugation, and were
assayed in triplicates using analyte-specific multiplexed cytokine/chemokine bead array
assays as reported by us previously.56
Transcriptomal profiling in human PBMCs—Detailed procedures for transcriptomal
profiling have been described by us previously.49 Briefly, fresh human PBMC samples were
stimulated with 10 μg/mL of 37b and 37f for two hours, and total RNA was extracted from
treated and negative control blood samples with QIAamp RNA Blood Mini Kit (Qiagen).
Subsequently, 160 ng of each of the RNA samples was used. The Human Genome
GeneChip U133 plus 2.0 oligonucleotide array (Affymetrix, Santa Clara, CA) was
employed. Established standard protocols at the KU Genomics Facility were performed on
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cRNA target preparation, array hybridization, washing, staining and image scanning. The
microarray data was first subjected to quality assessment using the Affymetrix GeneChip
Operating Software (GCOS). QC criteria included low background, low noise, detection of
positive controls, and a 5′/3′ ratio of < 3.0. To facilitate direct comparison of gene
expression data between different samples, the GeneChip data were first subjected to
preprocessing. This step involved scaling (in GCOS) data from all chips to a target intensity
value of 500, and further normalizations steps in GeneSpring GX (Agilent Technologies,
Santa Clara, CA). Prior to identifying target genes, genes that were detected as non-
expressed in all samples, i.e., those with absence calls, were filtered out. To identify genes
whose expression was changed by our compounds, a fold change threshold of 2.0 between
the compound treatment and the negative control was used.
Rabbit immunization and antigen-specific ELISA—All experiments were performed
at Harlan Laboratories (Indianapolis, IN) in accordance with institutional guidelines
(University of Kansas IACUC permit # 119-06). Cohorts of adult female New Zealand
White rabbits (n = 4 per cohort) were immunized intramuscularly in the flank region with
either 100 μg of bovine α-lactalbumin in 0.2 mL saline (unadjuvanted control), or 100 μg of
bovine α-lactalbumin plus 100 μg of 37b, 40, or 41 in 0.2 mL saline. Pre-immune test-
bleeds were first obtained via venipuncture of the marginal vein of the ear. Animals were
immunized on Days 1, 15 and 28. A final test-bleed was performed via the marginal vein of
the ear on Day 38. Sera were stored at -80 °C until used. Bovine α-lactalbumin-specific
ELISAs were performed in 384-well format using automated liquid handling methods as
described by us.42
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Abbreviations used
dsRNA double-stranded RNA
EC50 Half-maximal effective concentration
ESI-TOF Electrospray ionization-time of flight
HEK Human embryonic kidney
IL Interleukin
LPS Lipopolysaccharides
MHC Major histocompatibility complex
MyD88 myeloid differentiation primary response gene 88
NF-κB Nuclear factor-κB
PAMPs Pathogen associated molecular patterns
PBMCs Peripheral blood mononuclear cells
PRRs Pattern recognition receptors
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SAP Secreted alkaline phosphatase
SAR Structure activity relationship
ssRNA singlestranded RNA
TLR Toll like receptor
TNF-α Tumor necrosis factor-α
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Representative TLR7/8-agonistic heterocyclic small molecules.
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TLR7/8 agonistic scaffolds. R1 is typically alkyl or O-alkyl, R2 is alkyl or benzyl, and R3 is
usually alkyl, and OH in oxoadenines.
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Dose-response profiles of TLR8 agonism by select 2,3-diamino-furo[2,3-c]pyridines. Top:
TLR8 agonism by compounds derived from Schemes 2 and 5. Bottom: TLR8 agonism by
compounds derived from Schemes 6 and 7. Data points represent means and standard
deviations obtained on quadruplicates.
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Crystal structures of the salicylaldehyde-derived classic Groebke product (imidazo[1,2-
a]pyridine, 20), and a non-Groebke, pyridoxal-derived furo[2,3-c]pyridine, 28.
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Crystal structure (ORTEP view) of the non-Groebke furo[2,3-c]pyridine, 37e, obtained with
the use of pyridoxal as the aldehyde component.
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Dose-response profiles of proinflammatory cytokine induction in hPBMCs by compounds
28, 37a, 37b and 37f. Representative data from three independent experiments are
presented.
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Anti-bovine α-lactalbumin-specific IgG titers in rabbits adjuvanted with 37b, 40, and 41
(n=4, for each cohort). Box-plots of ratios of immune/pre-immune titers yielding absorbance
values of 1.0 are shown for the individual samples. Means and medians of titers are
represented by □ and − symbols within the box, respectively, and the X symbols indicate
the 1% and 99% percentile values.
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A two step one-pot synthetic process.
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Twenty-four membered diverse test-library.
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Possible cyclization pathways and proposed mechanism.
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Table 1
EC50 values of compounds in human TLR8-specific reporter gene assay
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Structure Compound Number TLR8-Agonistic Activity (μM)
29 9.79
35 Inactive

















Salunke et al. Page 39
Structure Compound Number TLR8-Agonistic Activity (μM)





37i 7.64 Low AUC
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37m 4.27 Very low AUC
37n Inactive
38a 2.25 Low AUC













Salunke et al. Page 41
Structure Compound Number TLR8-Agonistic Activity (μM)
38b 0.37 Low AUC
38c 0.85 Low AUC
39 3.37
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